Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging

Angiogenesis

Volumn 17, Issue 1, 2014, Pages 235-246

  Persigehl, Thorsten ^a,b   Ring, Janine ^a   Bremer, Christoph ^a   Heindel, Walter ^a   Holtmeier, Richard ^a   Stypmann, Jörg ^a   Claesener, Michael ^a   Hermann, Sven ^a   Schäfers, Michael ^a   Zerbst, Caroline ^a   Schliemann, Christoph ^a   Mesters, Rolf M ^a   Berdel, Wolfgang E ^a   Schwöppe, Christian ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Magnetic resonance imaging; Molecular imaging; Truncated tissue factor; Tumor targeting; Tumor vessel infarction; Tumor homing peptides; Ultrasound imaging; Vascular targeting

Indexed keywords

FLUORESCENT DYE; FX PRO; GLYCYLASPARAGINYLGLYCYLARGINYLALANYLHISTIDINYLALANINE; HYBRID PROTEIN; IODINE 123; SUPERPARAMAGNETIC IRON OXIDE; THROMBOPLASTIN; TRUNCATED TISSUE FACTOR NGR PROTEIN; TRUNCATED TISSUE FACTOR NGR PROTEIN I 123; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VEVO MICROMARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLEEDING; BLOOD CLOTTING; CANCER INHIBITION; COLLIMATOR; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE REFLECTANCE IMAGING; GAMMA CAMERA; HUMAN; HUMAN CELL; IMAGING SOFTWARE; IN VIVO STUDY; INFARCTION; MOLECULAR IMAGING; MOUSE; MULTIMODAL IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; THERAPY EFFECT; TISSUE PERFUSION; TUMOR VASCULARIZATION; TUMOR VESSEL INFARCTION; TUMOR XENOGRAFT; ULTRASOUND; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; HUMANS; INFARCTION; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84892717351     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9391-4     Document Type: Article

References (53)

1. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967-974
2. Kessler T, Bayer M, Schwöppe C, Liersch R, Mesters RM, Berdel WE (2010) Compounds in clinical Phase III and beyond. Recent Results Cancer Res 180:137-163
3. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307
4. Blankenberg FG, Levashova Z, Goris MG, Hamby CV, Backer MV, Backer JM (2011) Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. J Nucl Med 52(10):1630-1637
5. Mohamedali KA, Niu G, Luster TA, Thorpe PE, Gao H, Chen X, Rosenblum MG (2012) Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. Biochem Pharmacol 84(11):1534-1540
6. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha V beta 3 for angiogenesis. Science 264:569-571
7. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB (1999) NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59:2869-2874
8. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG (1989) A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108(3):1139-1148
9. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:867-874
10. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039
11. Felding-Habermann B, Ruggeri ZM, Cheresh DA (1992) Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 267(8):5070-5077
12. Kessler TA, Pfeifer A, Silletti S, Mesters RM, Berdel WE, Verma I, Cheresh D (2002) Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies. Ann Hematol 8(Suppl. 2):S69-S70
13. Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM (2007) Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets 8:257-268
14. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoshlahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722-727
15. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM (2000) Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci 97(22):12227-12232
16. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci 89:10832-10836
17. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380
18. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038
19. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-2407
20. Ruoslahti E (2000) Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:435-442
21. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000) Nat Biotechnol 18:1185-1190
22. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, Corti A (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:867-874
23. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M (2003) Cancer Res 63(21):7400-7409
24. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A (2004) Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 64(19):7150-7155
25. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A (2006) Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 12(1):175-182
26. van Laarhoven HW, Gambarota G, Heerschap A, Lok J, Verhagen I, Corti A, Toma S, Gallo Stampino C, van der Kogel A, Punt CJ (2006) Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs 24(1):27-36
27. Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, Protti MP, Ponzoni M, Toma S, Corti A (2006) Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol 43(10):1509-1518
28. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734-744
29. Kessler T, Bieker R, Padró T, Schwöppe C, Persigehl T, Bremer C, Kreuter M, Berdel WE, Mesters RM (2005) Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 11:6317-6324
30. Kessler T, Schwöppe C, Liersch R, Schliemann C, Hintelmann H, Bieker R, Berdel WE, Mesters RM (2008) Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol 5:1-8
31. Bieker R, Kessler T, Schwöppe C, Padró T, Persigehl T, Bremer C, Dreischalück J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE (2009) Infarction of tumor vessels by NGR-peptide directed targeting of tissue factor. Experimental results and first-in-man experience. Blood 113:5019-5027
32. Schwöppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, Dreischalück J, Ring J, Bremer C, Heindel W, Mesters RM, Berdel WE (2010) Tissue-factor fusion proteins induce occlusion of tumor vessels. Thromb Res 125(Suppl. 2):S143-S150
33. Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711-716
34. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS (2002) Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62:5470-5475
35. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58:4646-4653
36. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550
37. Persigehl T, Wall A, Kellert J, Ring J, Remmele S, Heindel W, Dahnke H, Bremer C (2010) Tumor blood volume determination by using susceptibility- corrected â̂†R2multiecho MR. Radiology 255(3):781-789
38. Dreischalück J, Schwöppe C, Spieker T, Kessler T, Tiemann K, Liersch R, Schliemann C, Kreuter M, Kolkmeyer A, Hintelmann H, Mesters RM, Berdel WE (2010) Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Int J Oncol 37:1389-1397
39. Von Maltzahn G, Park J-H, Lin KY, Singh N, Schwöppe C, Mesters R, Berdel WE, Ruoslahti E, Sailor MJ, Bhatia SN (2011) Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 10:545-552
40. Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, Müller-Tidow C, Mesters RM, Berdel WE (2013) Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor. J Med Chem 56(6):2337-2347
41. Bailey GS (1994) Labeling of peptides and proteins by radioiodination. Methods Mol Biol 32:441-448
42. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM (1998) NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40(6):793-799
43. Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P (2002) Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 223(2):432-438
44. Zhu H, Melder RJ, Baxter LT, Jain RK (1996) Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res 56(16):3771-3781
45. Lohmaier S, Ghanem A, Veltmann C, Sommer T, Bruce M, Tiemann K (2004) In vitro and in vivo studies on continuous echo-contrast application strategies using SonoVue in a newly developed rotating pump setup. Ultrasound Med Biol 30:1145-1151
46. Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijmann H, Meier N, Ebert W, Berdel WE, Heindel W, Mesters RM, Bremer C (2007) Antiangiogenic tumor treatment: early non-invasive monitoring with USPIO-enhanced MR Imaging in mice. Radiology 244(2):449-456
47. Von Wallbrunn A, Waldeck J, Höltke C, Zühlsdorf M, Mesters RM, Heindel W, Schäfers M, Bremer C (2008) In vivo optical imaging of CD13/APN-expression in tumor xenografts. J Biomed Opt 13(1):011007
48. Salmon BA, Salmon HW, Siemann DW (2007) Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur J Cancer 43(10):1622-1629
49. Nielsen T, Bentzen L, Pedersen M et al (2012) Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging. Clin Cancer Res 18(23):6469-6477
50. Kim KW, Lee JM, Jeon YS, et al. (2013) Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs. doi: 10.1007/s10637-012-9915-6
51. Shenoi MM, Iltis I, Choi J, et al. (2013) Nanoparticle Delivered Vascular Disrupting Agents (VDAs): Use of TNF-alpha conjugated Gold Nanoparticles for Multimodal Cancer Therapy. Mol Pharm. doi: 10.1021/mp300505w
52. Wang H, Sun X, Chen F et al (2009) Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44(1):44-53
53. Bohndiek SE, Kettunen MI, Hu DE et al (2010) Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy. Mol Cancer Ther 9(12):3278-3288